Venlafaxine
- Generic Name
- Venlafaxine
- Brand Names
- Effexor
- Drug Type
- Small Molecule
- Chemical Formula
- C17H27NO2
- CAS Number
- 93413-69-5
- Unique Ingredient Identifier
- GRZ5RCB1QG
- Background
Venlafaxine is an antidepressant and a serotonin and norepinephrine reuptake inhibitor (SNRI). Its active metabolite, desvenlafaxine, works by blocking the reuptake of serotonin and norepinephrine, which are key neurotransmitters in mood regulation. Venlafaxine is officially approved to treat major depressive disorder (MDD), generalized anxiety disorder (GAD...
- Indication
Venlafaxine is indicated for the management of major depressive disorder (MDD), generalized anxiety disorder (GAD), social anxiety disorder (SAD), and panic disorder.
- Associated Conditions
- Generalized Anxiety Disorder, Major Depressive Disorder (MDD), Migraine, Neuropathic Pain, Panic Disorder, Social Anxiety Disorder (SAD), Vasomotor Symptoms Associated With Menopause
- Associated Therapies
- -
CBT as an Adjunct to SRIs in the Treatment of BDD
- Conditions
- Interventions
- First Posted Date
- 2005-09-21
- Last Posted Date
- 2017-03-09
- Lead Sponsor
- Icahn School of Medicine at Mount Sinai
- Target Recruit Count
- 17
- Registration Number
- NCT00211809
- Locations
- 🇺🇸
Mount Sinai School of Medicine, New York, New York, United States
Pharmacological Intervention in Depression After Traumatic Brain Injury
- Conditions
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2017-03-17
- Lead Sponsor
- Virginia Commonwealth University
- Target Recruit Count
- 100
- Registration Number
- NCT00205491
- Locations
- 🇺🇸
Virginia Commonwealth University, Richmond, Virginia, United States
Venlafaxine for Hot Flashes After Breast Cancer
- Conditions
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2008-11-14
- Lead Sponsor
- Indiana University School of Medicine
- Target Recruit Count
- 75
- Registration Number
- NCT00198250
- Locations
- 🇺🇸
Indiana University Cancer Center, Indianapolis, Indiana, United States
Study Comparing Venlafaxine vs. Paroxetine in Panic Disorder
- Conditions
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2010-04-02
- Lead Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
- Target Recruit Count
- 70
- Registration Number
- NCT00195598
Antidepressant Medication Plus Donepezil for Treating Late-life Depression
- Conditions
- Interventions
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2013-02-06
- Lead Sponsor
- University of Pittsburgh
- Target Recruit Count
- 220
- Registration Number
- NCT00177671
- Locations
- 🇺🇸
University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States
Treatment of Geriatric Bipolar Mood Disorders: A Pilot Study
- Conditions
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2005-09-15
- Lead Sponsor
- University of Pittsburgh
- Target Recruit Count
- 60
- Registration Number
- NCT00177567
- Locations
- 🇺🇸
University of Pittsubrgh Medical Center, Pittsburgh, Pennsylvania, United States
🇺🇸University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States
Hippocampal Volume in Young Patients With Major Depression Before and After Combined Antidepressive Therapy
- First Posted Date
- 2005-09-08
- Last Posted Date
- 2020-12-14
- Lead Sponsor
- University of Erlangen-Nürnberg Medical School
- Target Recruit Count
- 80
- Registration Number
- NCT00150839
- Locations
- 🇩🇪
Department of Psychiatry and Psychotherapy, University Erlangen-Nuremberg, Erlangen, Bavaria, Germany
Free Venlafaxine Treatment for Marijuana Addiction and Depression - 1
- First Posted Date
- 2005-08-18
- Last Posted Date
- 2019-04-24
- Lead Sponsor
- New York State Psychiatric Institute
- Target Recruit Count
- 123
- Registration Number
- NCT00131456
- Locations
- 🇺🇸
New York State Psychiatric Institute, New York, New York, United States
A Comparison of Duloxetine Hydrochloride, Marketed Comparator, and Placebo in the Treatment of Generalized Anxiety Disorder
- Conditions
- First Posted Date
- 2005-07-22
- Last Posted Date
- 2007-11-06
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 480
- Registration Number
- NCT00122850
- Locations
- 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Seattle, Washington, United States
A Comparison of Duloxetine Hydrochloride, Marketed Comparator, and Placebo in the Treatment of Generalized Anxiety Disorder
- Conditions
- First Posted Date
- 2005-07-22
- Last Posted Date
- 2007-10-18
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 560
- Registration Number
- NCT00122837
- Locations
- 🇬🇧
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. test, Glasgow, Scotland, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.